Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Addrenex Pharmaceuticals specializes in developing small molecule drugs targeting the adrenergic system to treat conditions such as ADHD, hypertension, and narcolepsy. Its lead product Clonicel® has demonstrated positive results in two phase III studies for ADHD. The company also has compounds in development or preclinical stages addressing menopausal flushing, insomnia, pain, and migraines. North American rights to market Clonicel are licensed to Sciele Pharma/Shionogi. ADX-N05 represents an expansion into narcolepsy with promising preclinical data.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Addrenex Pharmaceuticals.